

FOR IMMEDIATE RELEASE

Spectrum Dynamics to Showcase 2 New Break Through Clinical Applications for Cardiac Imaging at the 2008 Society Of Nuclear Medicine Meeting In New Orleans

Orangeburg, New York, June 13th 2008 – Spectrum Dynamics, announced today that it will show for the first time the feasibility of two new D-SPECT™ based clinical protocols that can dramatically reduce patient procedure time, improve clinical accuracy and provide new diagnostic information not possible from conventional nuclear cardiology systems.

The D-SPECT, with its nine CZT based detectors and exceptionally good energy resolution, enables the simultaneous acquisition of images with multiple radionuclides without having the different energy photons interfering with each other and degrading image quality. This capability provides the foundation for simultaneous stress and rest myocardial perfusion imaging using Thallium (Tl) and Technetium (Tc), thus eliminating the need for the patient to have 2 separate imaging sessions. In addition, since the stress and the rest studies are acquired simultaneously, the registration between the stress and the rest study is perfect and this may potentially improve the diagnostic confidence.

A typical stress and rest myocardial perfusion study takes up to 3 or 4 hours as the stress and the rest imaging is done separately, and separated by multiple hours meaning the patient must come to the lab at least twice with 2 to 4 hours in between. The new Spectrum Dynamics application reduces the entire procedure (assumes pharmaceutical stress) to approximately 20 minutes with a single camera acquisition.

A number of clinical studies using a 15 minute simultaneous dual isotope acquisition protocol and also imaging the same patients on a conventional a camera (sequentially) for comparison, has been performed recently at the University College of London Hospital in the UK.

Professor Simona Ben Haim, MD, DSc from the University College of London Hospital stated: "Preliminary conclusions are that dual radio-radionuclide myocardial perfusion imaging with D-SPECT offered significantly reduced imaging time, improved image quality and enabled fast, high quality simultaneous dual radionuclide myocardial perfusion imaging in one imaging session".

Another new application having significant new clinical potential is Dynamic SPECT. Dynamic SPECT Imaging is a new way to acquire 3D data with very high temporal resolution. Instead of one long SPECT acquisition as conventional cameras do, the D-SPECT is capable of acquiring short, Dynamic SPECT acquisitions, essential in capturing rapid transit times of the radionuclide bolus through the heart and its subsequent extraction by the myocardium. This unique innovation could potentially lead to improved quantitative capabilities with SPECT, including for example estimates of coronary perfusion reserve that may improve detection of coronary artery disease.

We are extremely excited to show the market what we believe to be the first clinical Dynamic SPECT images acquired on a high sensitivity solid state camera installed at a clinical site. Many consider absolute quantification the "holy grail" of nuclear cardiac imaging and this would potentially provide a big boost for SPECT imaging utilization which is currently challenged due to previous lack of technological and clinical innovation, stated Josh Gurewitz, Vice President of Sales and Marketing for Spectrum Dynamics. "Additionally, the potential of this unique capability on the D-SPECT goes beyond just cardiology into other areas of nuclear imaging as well, including infection imaging and Oncology" added Gurewitz.

About Spectrum Dynamics

Spectrum Dynamics LLC, with offices in New York, California and research and development facilities in Caesarea, Israel is a pioneering medical device company focused on personalized molecular imaging and applications. Spectrum Dynamics will revolutionize the practice of nuclear cardiology, and eventually all nuclear medicine applications, by dramatically enhancing workflow and providing new clinical applications not possible with conventional technology. Additional information can be found at www.spectrum-dynamics.com

Statement

This press release may contain forward-looking statements about Spectrum Dynamics, including projections about our business and the nuclear medicine market. Those forward-looking statements are not guarantees of future performance and actual results could differ.

-END-

For further information please contact:

Josh Gurewitz, Vice President of Sales & Marketing, Spectrum Dynamics
Tel: (925) 831-0515, e-mail: JoshG@spectrum-dynamics.com